Systemic gene therapy by intestinal cell transformation
US6225290A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 19, 1996 |
| Grant date | May 1, 2001 |
| Priority date | — |
| Expiry date | Sep 19, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/61
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Intestinal epithelial cells of a mammalian subject are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect. Intestinal cell transformation is accomplished by administration of a formulation composed primarily of naked DNA, and is preferably administered orally. Oral or other intragastrointestinal routes of administration provide a simple method of administration, while the use of naked nucleic acid avoids the complications associated with use of viral vectors to accomplish gene therapy. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed intestinal epithelial cells provide short or long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.